EUVIMEDEUVIMED entdecken
CrossrefInfokarte

No demonstrated superiority of tropomyosin (Pen a 1) sIgE over crude shrimp sIgE in children

Noriyuki Yanagida, Hironaga Yoshimoto, Kanako Ogura, Ken‐ichi Nagakura, Kyohei Takahashi, Kiyotake Ogura, Sakura Sato, Motohiro Ebisawa

Pediatric Allergy and Immunology · 2026-10 · 37 (10)

DOI: 10.1111/pai.70506 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Tropomyosin (Pen a 1)‐specific IgE (sIgE) is a proposed diagnostic marker for shrimp allergy; however, its superiority over crude shrimp sIgE is unclear. This study aimed to determine whether Pen a 1 sIgE is superior to crude shrimp sIgE for predicting oral food challenge (OFC) outcomes in children. Methods We retrospectively analyzed children who underwent OFCs using ≥40 g heated shrimp and had both shrimp sIgE and Pen a 1 sIgE data. Areas under the receiver operating characteristic curves (AUCs) were compared using the DeLong test, and the paired AUC difference with its 95% confidence interval (CI) was estimated. Results Of 204 patients (median age 6.2 years; 70% male), 33 (16%) had a positive OFC. The AUCs for shrimp sIgE (0.629; 95% CI, 0.535–0.723) and Pen a 1 sIgE (0.622; 95% CI, 0.524–0.718) did not differ significantly (difference, 0.007; 95% CI, −0.069 to 0.083; DeLong p = .850). Pen a 1 sIgE correlated strongly with shrimp sIgE ( r = .767, p < .001). Among 190 patients with Dermatophagoides pteronyssinus (Der p) sIgE data, Der p sIgE correlated weakly with both markers ( r = .321 and .217) and did not differ by OFC outcome ( p = .612). Conclusion Superiority of Pen a 1 sIgE over crude shrimp sIgE was not demonstrated. The strong correlation suggests that tropomyosin is a major IgE‐binding component of the crude extract. OFC remains essential. image

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →